Tisotumab vedotin-tftv - Biologic Drug Details

Summary for tisotumab vedotin-tftv

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tisotumab vedotin-tftv Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tisotumab vedotin-tftv Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tisotumab vedotin-tftv Derived from Patent Text Search

No patents found based on company disclosures

Last updated: February 12, 2026

What is the current market status of tisotumab vedotin-tftv?

Tisotumab vedotin-tftv (brand name: Tivdak) is the first FDA-approved antibody-drug conjugate (ADC) targeted at recurrent or metastatic cervical cancer. It received accelerated approval in September 2021 based on phase 2 data showing objective response rates of approximately 24%. As a new biologic, its market penetration remains limited but growing, with sales driven primarily by cervical cancer treatment indications within the US, Europe, and select Asian markets.

How does tisotumab vedotin-tftv fit within the biologic landscape?

Tivdak is distinguished within the ADCs segment by its mechanism targeting tissue factor (TF), a protein overexpressed in various cancers. ADCs such as trastuzumab emtansine and brentuximab vedotin are mature competitors across oncology. However, Tivdak’s unique target opens potential for extended indications across multiple solid tumors.

Market adoption factors include limited approved indications, competition from chemotherapies, targeted agents, and immunotherapies, and evolving complexity of treatment algorithms. Its status as a first-in-class anti-TF ADC offers a competitive edge, but commercialization depends heavily on real-world efficacy data and companion diagnostics development.

What are the primary revenue streams for tisotumab vedotin-tftv?

Sales originate from its approved indication for cervical cancer, with estimates indicating:

• Year-one US sales reached approximately $30–50 million, largely from early adopters.
• European and Asian markets have started incremental launches, but data remains scarce.
• Given its recent FDA approval, sales growth is projected to scale up over mid- to long-term periods, contingent on label expansions and post-approval studies.

Pricing strategies position Tivdak at a premium level for ADCs. The wholesale acquisition cost (WAC) per dose exceeds $10,000, assuming a typical treatment course of 3–4 doses. Reimbursement varies by country, influenced by national health policies and payer coverage.

What are the key factors influencing Tivdak's market trajectory?

• Regulatory approvals beyond cervical cancer: Expanding into other TF-overexpressing tumors could substantially increase sales.
• Clinical trial outcomes: Ongoing phase 3 trials for SCCHN and other solid tumors aim to validate efficacy. Positive results would accelerate uptake.
• Companion diagnostics development: To enhance precision, assays identifying TF overexpression could improve patient selection, boosting response rates.
• Pricing and reimbursement policies: Negotiations with payers and government agencies will determine market access and patient affordability.
• Competitive landscape: Surging pipeline ADCs and immune checkpoint inhibitors could challenge Tivdak’s share, particularly if combination or pipeline products demonstrate superior outcomes.

How is the financial outlook evolving?

The financial trajectory remains conservative amid early sales data but shows potential for rapid growth if ongoing trials succeed.

• Revenue estimates: Analysts project revenues reaching $150–200 million globally in 2024, driven by primary cervical cancer approval and initial extensions.
• Margins: With manufacturing costs and R&D expenses, gross margins are expected to be in the 50–60% range, typical of ADCs.
• Investment focus: Companies investing in ADC development and biomarker-driven approaches may see M&A activity or licensing deals, affecting market dynamics.

What are the key risks and opportunities?

Risks:

• Delayed or failed expansion into other indications.
• Unfavorable reimbursement decisions.
• Emergence of competing therapies with superior efficacy or reduced toxicity.

Opportunities:

• New labels for additional cancers enhance revenue potential.
• Combination therapies could increase response rates and patient survival.
• Biomarker integration allows for targeted patient stratification, improving clinical outcomes.

Closing Summary

Tivdak is a pioneer in TF-targeted ADCs with initial approval for cervical cancer, setting the stage for potential broader application. Its market growth hinges on clinical success, regulatory approval for new indications, pricing, and competitive pressures within oncology biologics. While early sales remain modest, the long-term outlook is promising if further evidence can expand its reach and solidify its role in combination regimens.

Key Takeaways

• Tisotumab vedotin-tftv is an FDA-approved ADC targeting tissue factor for cervical cancer, with early revenue estimates around $30–50 million in the US.
• Its market expansion depends on positive clinical trial results and regulatory approvals for additional indications.
• Pricing is premium, with potential for growth if reimbursement policies are favorable.
• Competition includes established ADCs and emerging immunotherapies; its unique TF target offers an advantage if clinical success continues.
• Longer-term growth relies on biomarker-driven patient selection, combination strategies, and global market access.

FAQs

1. What is the primary approved use of tisotumab vedotin-tftv?
   It is approved for recurrent or metastatic cervical cancer following chemotherapy failure.

2. Can Tivdak be used for other cancer types now?
   Not currently; ongoing trials aim to evaluate efficacy in other solid tumors, including head and neck cancers.

3. How does the pricing of Tivdak compare to other ADCs?
   It is positioned at a premium compared to some ADCs due to the novel target and initial label, with costs exceeding $10,000 per dose.

4. What factors could accelerate Tivdak's market growth?
   Label expansion to other cancers, positive trial outcomes, and favorable reimbursement policies.

5. What are the main challenges facing Tivdak's commercial success?
   Competition from other therapies, potential limited indications, and reimbursement hurdles.

---

References

[1] U.S. Food and Drug Administration. (2021). FDA approves tisotumab vedotin for cervical cancer.
[2] BioPharm Insight. (2023). ADC market analysis and sales projections.
[3] ClinicalTrials.gov. (2023). Ongoing trials for tisotumab vedotin in other solid tumors.